157 related articles for article (PubMed ID: 34329741)
1. Selective progesterone receptor blockade prevents BRCA1-associated mouse mammary tumors through modulation of epithelial and stromal genes.
Lee O; Bosland MC; Wang M; Shidfar A; Hosseini O; Xuei X; Patel P; Schipma MJ; Helenowski I; Kim JJ; Clare SE; Khan SA
Cancer Lett; 2021 Nov; 520():255-266. PubMed ID: 34329741
[TBL] [Abstract][Full Text] [Related]
2. Progesterone receptor antagonism inhibits progestogen-related carcinogenesis and suppresses tumor cell proliferation.
Lee O; Choi MR; Christov K; Ivancic D; Khan SA
Cancer Lett; 2016 Jul; 376(2):310-7. PubMed ID: 27080304
[TBL] [Abstract][Full Text] [Related]
3. The breast cancer susceptibility gene BRCA1 regulates progesterone receptor signaling in mammary epithelial cells.
Ma Y; Katiyar P; Jones LP; Fan S; Zhang Y; Furth PA; Rosen EM
Mol Endocrinol; 2006 Jan; 20(1):14-34. PubMed ID: 16109739
[TBL] [Abstract][Full Text] [Related]
4. Progesterone receptor A stability is mediated by glycogen synthase kinase-3β in the Brca1-deficient mammary gland.
Wang S; Li Y; Hsu PH; Lee SY; Kim Y; Lee EYP
J Biol Chem; 2013 Sep; 288(36):26265-26274. PubMed ID: 23880761
[TBL] [Abstract][Full Text] [Related]
5. BRCA1 mutation influences progesterone response in human benign mammary organoids.
Davaadelger B; Choi MR; Singhal H; Clare SE; Khan SA; Kim JJ
Breast Cancer Res; 2019 Nov; 21(1):124. PubMed ID: 31771627
[TBL] [Abstract][Full Text] [Related]
6. Progesterone receptor antagonists reverse stem cell expansion and the paracrine effectors of progesterone action in the mouse mammary gland.
Ranjan M; Lee O; Cottone G; Mirzaei Mehrabad E; Spike BT; Zeng Z; Yadav S; Chatterton R; Kim JJ; Clare SE; Khan SA
Breast Cancer Res; 2021 Aug; 23(1):78. PubMed ID: 34344445
[TBL] [Abstract][Full Text] [Related]
7. Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist.
Poole AJ; Li Y; Kim Y; Lin SC; Lee WH; Lee EY
Science; 2006 Dec; 314(5804):1467-70. PubMed ID: 17138902
[TBL] [Abstract][Full Text] [Related]
8. Proliferation and ovarian hormone signaling are impaired in normal breast tissues from women with BRCA1 mutations: benefit of a progesterone receptor modulator treatment as a breast cancer preventive strategy in women with inherited BRCA1 mutations.
Communal L; Vilasco M; Hugon-Rodin J; Courtin A; Mourra N; Lahlou N; Le Guillou M; Perrault de Jotemps M; Chauvet MP; Chaouat M; Pujol P; Feunteun J; Delaloge S; Forgez P; Gompel A
Oncotarget; 2016 Jul; 7(29):45317-45330. PubMed ID: 27246982
[TBL] [Abstract][Full Text] [Related]
9. Characterization of Molecular Changes in Endometrium Associated With Chronic Use of Progesterone Receptor Modulators: Ulipristal Acetate Versus Mifepristone.
Kannan A; Bhurke A; Sitruk-Ware R; Lalitkumar PG; Gemzell-Danielsson K; Williams ARW; Taylor RN; Bagchi MK; Bagchi IC
Reprod Sci; 2018 Mar; 25(3):320-328. PubMed ID: 29241443
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of Telapristone Acetate (CDB4124) on Progesterone Receptor Action in Breast Cancer Cells.
Davaadelger B; Murphy AR; Clare SE; Lee O; Khan SA; Kim JJ
Endocrinology; 2018 Oct; 159(10):3581-3595. PubMed ID: 30203004
[TBL] [Abstract][Full Text] [Related]
11. RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers.
Nolan E; Vaillant F; Branstetter D; Pal B; Giner G; Whitehead L; Lok SW; Mann GB; ; Rohrbach K; Huang LY; Soriano R; Smyth GK; Dougall WC; Visvader JE; Lindeman GJ
Nat Med; 2016 Aug; 22(8):933-9. PubMed ID: 27322743
[TBL] [Abstract][Full Text] [Related]
12. Anti-Tumoral Effects of Anti-Progestins in a Patient-Derived Breast Cancer Xenograft Model.
Esber N; Cherbonnier C; Resche-Rigon M; Hamze A; Alami M; Fagart J; Loosfelt H; Lombès M; Chabbert-Buffet N
Horm Cancer; 2016 Apr; 7(2):137-47. PubMed ID: 26941094
[TBL] [Abstract][Full Text] [Related]
13. Selective Progesterone Receptor Modulators in Early-Stage Breast Cancer: A Randomized, Placebo-Controlled Phase II Window-of-Opportunity Trial Using Telapristone Acetate.
Lee O; Sullivan ME; Xu Y; Rogers C; Muzzio M; Helenowski I; Shidfar A; Zeng Z; Singhal H; Jovanovic B; Hansen N; Bethke KP; Gann PH; Gradishar W; Kim JJ; Clare SE; Khan SA
Clin Cancer Res; 2020 Jan; 26(1):25-34. PubMed ID: 31570566
[TBL] [Abstract][Full Text] [Related]
14. BRCA1 Attenuates Progesterone Effects on Proliferation and NFκB Activation in Normal Human Mammary Epithelial Cells.
Hilton HN; Patterson McDonald LJ; Santucci N; van der Bent FR; Silvestri A; Graham JD; Clarke CL
J Mammary Gland Biol Neoplasia; 2019 Sep; 24(3):257-270. PubMed ID: 31104199
[TBL] [Abstract][Full Text] [Related]
15. Altered AIB1 or AIB1Δ3 expression impacts ERα effects on mammary gland stromal and epithelial content.
Nakles RE; Shiffert MT; Díaz-Cruz ES; Cabrera MC; Alotaiby M; Miermont AM; Riegel AT; Furth PA
Mol Endocrinol; 2011 Apr; 25(4):549-63. PubMed ID: 21292825
[TBL] [Abstract][Full Text] [Related]
16. Dissecting the heterogeneity and tumorigenesis of BRCA1 deficient mammary tumors via single cell RNA sequencing.
Sun H; Zeng J; Miao Z; Lei KC; Huang C; Hu L; Su SM; Chan UI; Miao K; Zhang X; Zhang A; Guo S; Chen S; Meng Y; Deng M; Hao W; Lei H; Lin Y; Yang Z; Tang D; Wong KH; Zhang XD; Xu X; Deng CX
Theranostics; 2021; 11(20):9967-9987. PubMed ID: 34815798
[No Abstract] [Full Text] [Related]
17. Next step in the development of mesoprogestins: the preclinical profile of EC313.
Błaszczak-Świątkiewicz K; Krupa A; Mnich E; Elger W; Oettel M; Nair H; Wierzbicki M; Sieroszewski P; Shaked Z
Front Endocrinol (Lausanne); 2023; 14():1201547. PubMed ID: 37766684
[TBL] [Abstract][Full Text] [Related]
18. Ulipristal Acetate Antagonizes the Inhibitory Effect of Progesterone on Ciliary Beat Frequency and Upregulates Steroid Receptor Expression Levels in Human Fallopian Tubes.
Yuan J; Zhao W; Yan M; Zhu Q; Qin G; Qiu J; Zhang J
Reprod Sci; 2015 Dec; 22(12):1516-23. PubMed ID: 26045548
[TBL] [Abstract][Full Text] [Related]
19. Embryonic mammary signature subsets are activated in Brca1-/- and basal-like breast cancers.
Zvelebil M; Oliemuller E; Gao Q; Wansbury O; Mackay A; Kendrick H; Smalley MJ; Reis-Filho JS; Howard BA
Breast Cancer Res; 2013 Mar; 15(2):R25. PubMed ID: 23506684
[TBL] [Abstract][Full Text] [Related]
20. Selective Progesterone Receptor Modulators-Mechanisms and Therapeutic Utility.
Islam MS; Afrin S; Jones SI; Segars J
Endocr Rev; 2020 Oct; 41(5):. PubMed ID: 32365199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
